Hydrocortisone — Why It Is Dangerous, Side Effects and Withdrawal Syndrome

Effective | Toxic

Names Under Which Hydrocortisone Is Available

The international nonproprietary name is hydrocortisone, Hydrocortisone; the natural hormone with the same structure is called cortisol, Cortisol. Medicinal products contain hydrocortisone, hydrocortisone acetate, hydrocortisone sodium succinate, as well as hydrocortisone butyrate and other esters intended for topical use. Available dosage forms include tablets and granules, injectable solutions and powders, creams, ointments, lotions, skin solutions, rectal formulations and other topical preparations. Brand names include Cortef, Solu-Cortef, Plenadren, Efmody, Alkindi, Hydrocortone, Anusol-HC, Proctocort and numerous products labelled simply as Hydrocortisone. Hydrocortisone is also included in combination creams, ointments, ear preparations and rectal products together with neomycin, fusidic acid, clotrimazole, miconazole, natamycin, lidocaine, pramoxine and other substances. Such combinations create a risk of unrecognised duplication of the glucocorticoid, especially when a patient simultaneously uses an ointment, suppositories, ear drops and a systemic medicine sold under different names.

Why Hydrocortisone Is Considered Harmless and Where the Real Risk Begins

Hydrocortisone is often perceived as a “mild hormonal ointment” because low-concentration creams are available without a prescription, quickly reduce itching and redness and do not cause immediate pain. However, the disappearance of inflammation does not mean that its cause has been eliminated: the medicine suppresses the immune response, may mask a bacterial, fungal or viral infection and create the impression of improvement while the pathological process continues. Systemic formulations affect not only the inflamed area but also carbohydrate, protein, fat and water-electrolyte metabolism, immunity, blood vessels, bones and the body’s own cortisol secretion. Even a topical product can be absorbed systemically when applied over a large area, to damaged or thin skin, under a dressing, within skin folds, on the face or for a prolonged period. The most common everyday mistake is to reapply it whenever symptoms return without establishing the diagnosis, while gradually increasing both the treated area and the duration of treatment.

Side Effects During the First Hours and Days of Use

Topical use may cause burning, itching, irritation, dryness, folliculitis, acneiform eruptions, heat rash, perioral dermatitis, changes in pigmentation and allergic contact dermatitis. On infected skin, suppression of the local immune response may accelerate the spread of infection or alter its appearance. Contact with the eyes and prolonged use around the eyelids increase the risk of ophthalmic complications. Following systemic administration or injection, possible effects include increased blood pressure, sodium and fluid retention, oedema, potassium loss, hyperglycaemia, agitation, insomnia, emotional instability, dyspepsia and worsening of an infection. Severe early reactions include anaphylaxis, marked hypokalaemia, acute psychiatric disorders, gastrointestinal bleeding and decompensation of diabetes mellitus. High doses may suppress fever and inflammatory signs, which means that a severe infection can sometimes develop without the expected clinical presentation.

What Happens During Prolonged or Repeated Use

Prolonged systemic treatment may cause iatrogenic Cushing’s syndrome: weight gain with redistribution of body fat, a moon-shaped face, muscle weakness, thinning of the skin, bruising, stretch marks, hyperglycaemia, arterial hypertension and lipid metabolism disorders. At the same time, the risk of osteoporosis, fractures, aseptic bone necrosis, cataracts, glaucoma, infections, ulcer-related complications, growth retardation in children and psychiatric disorders increases. The most significant delayed risk is suppression of the hypothalamic-pituitary-adrenal axis: the body reduces its own cortisol production and becomes dependent on an external supply of glucocorticoids. Adrenal insufficiency may persist for months after treatment is discontinued. Repeated courses of topical hydrocortisone cause skin atrophy, telangiectasia, stretch marks, delayed healing, secondary infection and steroid dermatitis; the face, eyelids, genital area and skin folds are damaged particularly quickly. The absence of early burning or irritation does not protect against systemic adrenal suppression or progressive skin atrophy.

Contraindications and High-Risk Groups

Systemic hydrocortisone is particularly dangerous in untreated systemic fungal infections, active severe infections without adequate antimicrobial therapy, uncontrolled diabetes mellitus, severe arterial hypertension, heart failure, hypokalaemia, active peptic ulcer disease, severe osteoporosis, glaucoma, psychosis and conditions associated with a high risk of thrombosis or gastrointestinal bleeding. In latent tuberculosis, herpes infection, parasitic diseases and chronic infections, immunosuppression may cause reactivation or dissemination of the process. The effects of hydrocortisone may be enhanced in cirrhosis and hypothyroidism. Children develop systemic effects from topical formulations more easily because of their greater skin surface area relative to body weight. A topical preparation must not be used as the sole treatment for bacterial, viral or fungal skin lesions, rosacea, ulcers or a local infection. In contrast, for patients with confirmed adrenal insufficiency, hydrocortisone is essential replacement therapy: both unjustified discontinuation and failure to take a stress dose during infection, injury or surgery are dangerous.

Dangerous Interactions

Combining systemic hydrocortisone with nonsteroidal anti-inflammatory drugs and acetylsalicylic acid is highly undesirable because it increases the risk of ulcers and gastrointestinal bleeding. Amphotericin B, loop and thiazide diuretics, stimulant laxatives and other potassium-lowering agents increase the likelihood of severe hypokalaemia and associated cardiac rhythm disturbances; under these conditions, the toxicity of cardiac glycosides also rises. Ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat and other strong CYP3A4 inhibitors slow hydrocortisone metabolism and intensify systemic steroid complications; a similar interaction may occur with grapefruit juice. Enzyme inducers, including rifampicin, phenytoin, carbamazepine and barbiturates, may reduce hydrocortisone concentrations and cause inadequate replacement therapy. The medicine weakens the effects of glucose-lowering and antihypertensive agents and alters the action of anticoagulants and salicylates. High immunosuppressive doses are incompatible with live vaccines. Alcohol does not cause a specific chemical reaction with hydrocortisone, but it increases gastric irritation, sleep disturbances, fluctuations in glucose levels and the likelihood of dosing errors. Hidden duplication may occur when tablets, injections, ointments, ear drops and rectal combination products containing hydrocortisone are used at the same time.

Patient Errors

The most common mistake is to regard hydrocortisone as an ordinary anti-itch medicine and apply it to any area of redness without a diagnosis. This can mask dermatophytosis, bacterial infection, herpes, scabies, perioral dermatitis and an allergy to a component of the medicine itself. The risk rises sharply when the product is applied in a thick layer, under plastic film or a tight dressing, to the face, eyelids, genital area, damaged skin or a large surface. Parents often apply the cream under a nappy, effectively creating an occlusive dressing and increasing absorption. Typical errors with systemic formulations include independently increasing the dose when the condition worsens, missing replacement therapy, failing to increase the dose during a severe infection and abruptly stopping the medicine after prolonged treatment. Another mistake is not informing the doctor about the medicine because of the belief that “it is only an ointment,” even though the combined exposure from several topical and systemic formulations may suppress adrenal function. The over-the-counter status of certain creams does not turn a hormonal medicine into a safe cosmetic product.

Hydrocortisone Overdose and Poisoning

No single one-time “toxic dose” of hydrocortisone has been established that would apply to every patient: the danger depends on the formulation, duration of use, coexisting diseases, body weight, liver function, drug interactions and baseline adrenal function. Acute fatal poisoning with glucocorticoids is rare, and there is no specific antidote. A significant overdose may cause nausea, vomiting, sodium and water retention, oedema, increased blood pressure, hyperglycaemia, hypokalaemia, agitation, mania or psychosis and gastrointestinal bleeding. The main practical danger is more often associated not with a single dose but with repeated high doses and chronic excess: Cushing’s syndrome, infections, metabolic disorders, osteoporosis and adrenal suppression gradually develop. Abrupt discontinuation after such a course may cause secondary adrenal insufficiency with profound weakness, a sharp fall in blood pressure, vomiting, abdominal pain, hypoglycaemia, impaired consciousness, shock and risk of death. During replacement therapy, both overdose and an insufficient dose require assessment: excess causes hypercortisolism, while missing the medicine during stress may lead to an adrenal crisis. If a significant overdose or crisis is suspected, one must not wait for fully developed symptoms; urgent assessment of electrolytes, glucose and haemodynamics, together with symptomatic treatment, is required.

A Safe Integrative Alternative to Hydrocortisone

Hydrocortisone cannot be replaced by a single herbal remedy because it is used for fundamentally different purposes. In chronic inflammation of the joints and soft tissues, the most evidence-based oral option is a standardised dry extract of Boswellia serrata. Boswellic acids inhibit the 5-lipoxygenase pathway and the formation of pro-inflammatory leukotrienes without causing the suppression of the hypothalamic-pituitary-adrenal axis that is typical of systemic glucocorticoids. Clinical trials and meta-analyses show reductions in pain, stiffness and functional impairment, mainly in osteoarthritis, but Boswellia does not act as rapidly or as broadly as systemic hydrocortisone and is not intended to treat anaphylaxis, a severe asthma exacerbation, an autoimmune crisis or airway oedema.

For oral use, a dry Boswellia serrata extract standardised to contain at least 65% boswellic acids is used. The basic regimen specified for this extract is 250–300 mg twice daily after meals. The effect usually develops gradually, so the medicine is assessed over the course of treatment rather than after the first dose. Possible adverse effects include nausea, heartburn, abdominal discomfort, diarrhoea and an allergic reaction. In active peptic ulcer disease, pregnancy, breastfeeding, during anticoagulant therapy and in marked polypharmacy, the regimen must be agreed with a specialist.

For limited, non-infected dermatitis, a topical alternative may be an ointment containing dry extracts of Nigella sativa and Scutellaria baicalensis. Clinical data for Nigella sativa are limited: in a small comparative study, a black seed preparation reduced the severity of hand eczema to a degree comparable with betamethasone. This does not mean that it has been proven equivalent to hydrocortisone for all dermatoses. For Scutellaria baicalensis, anti-inflammatory activity after topical use has been confirmed mainly in experimental models of contact and atopic dermatitis; there is still no full clinical evidence base for a finished combination of the two extracts.

Ointment Made from Nigella sativa and Scutellaria baicalensis Extracts

To prepare 100 g of ointment, use 5 g of dry Nigella sativa extract, 5 g of dry Scutellaria baicalensis extract, 70 g of coconut oil, 15 g of beeswax and 5 g of lanolin.

Heat the coconut oil and beeswax in a water bath to approximately 55–60 °C until completely melted. Add the lanolin and mix. Separately triturate each dry extract thoroughly with a small amount of the warm base until a uniform paste without dry lumps is obtained. Gradually incorporate the pastes into the main mixture while stirring continuously. Once the extracts are evenly distributed, cool the ointment to approximately 40 °C and transfer it into clean, dry, dark-glass jars.

This preparation is an individual extemporaneous formulation rather than a registered medicinal product with confirmed stability and standardised release. Dry extracts may not dissolve completely in the fatty base, so uniformity, odour, colour changes and signs of separation should be assessed before use. Separate formulations of black seed and skullcap ointments published on product pages also use coconut oil, wax and a 5% topical concentration of skullcap extract.

Apply the ointment in a thin layer to a small area of non-infected skin once or twice daily. Before the first full application, perform a patch test on an area of approximately 1 cm² and observe the reaction for at least 24 hours. If burning, itching, swelling, oozing or redness increases, wash the product off and do not use it again. Nigella sativa itself may cause allergic contact dermatitis.

Do not apply the ointment to the eyelids, mucous membranes, open wounds, deep fissures, ulcers, purulent lesions, active herpes, extensive weeping surfaces or areas where a fungal infection is suspected. It must not be used to mask a rash of unknown origin. Widespread dermatitis, fever, pain, blisters, necrosis, purulent discharge or rapid enlargement of the affected area requires diagnosis rather than further application of an anti-inflammatory ointment.

Store the ointment in a tightly closed jar in a cool, dark place and prevent water from entering it. For a homemade formulation without microbiological control, it is reasonable to prepare only a small amount and use it within 30 days. An unusual odour, mould, gas formation, separation or a marked change in colour is grounds for disposal.

Neither Boswellia serrata nor a topical combination of Nigella sativa and Scutellaria baicalensis can replace hydrocortisone in primary or secondary adrenal insufficiency. In these conditions, hydrocortisone performs the function of the missing cortisol, and its sudden discontinuation may cause an adrenal crisis and death.

The Real Effectiveness of Hydrocortisone and Medical Errors

Hydrocortisone is genuinely effective as replacement therapy in adrenal insufficiency, as an emergency treatment for adrenal crisis and as a rapidly acting anti-inflammatory and immunosuppressive medicine in a number of severe allergic, autoimmune and inflammatory conditions. Topical formulations quickly reduce itching, erythema and inflammation in confirmed steroid-responsive dermatoses. The medicine suppresses the inflammatory response, but in most such situations it does not eliminate the underlying cause of the disease: infection, an allergen, disruption of the skin barrier or an autoimmune mechanism.

The main medical errors are prescribing topical hydrocortisone without first excluding a fungal, bacterial or viral infection; prolonged use on the face, eyelids and skin folds; failure to limit the application area; repeating courses without reconsidering the diagnosis; and prescribing systemic treatment without assessing glucose, blood pressure, electrolytes, infection risk and concomitant therapy. It is no less dangerous to prescribe a prolonged systemic course without giving the patient a written dose-tapering schedule. In adrenal insufficiency, the opposite error is an inadequate replacement dose or failure to increase it during infection, surgery or severe injury.

Boswellia may be considered for chronic inflammatory pain and osteoarthritis when immediate immunosuppression is not required. A topical combination of Nigella sativa and Scutellaria baicalensis may be used for limited, mild, non-infected skin inflammation after the diagnosis has been established. These remedies must not be presented as a universal natural hydrocortisone: they have different targets, act more slowly and have a substantially narrower evidence base.

Safety Monitoring During Treatment

During short-term, limited use of topical hydrocortisone, the condition of the skin should be monitored for increased redness, the appearance of pustules, oozing, tenderness, fissures, telangiectasia, thinning of the skin, spread of the lesion or a change in its appearance. When applied near the eyes, eye pain, blurred vision, photophobia and deterioration of vision are reasons to stop self-treatment immediately.

During systemic therapy, blood pressure, body weight, oedema, blood glucose and electrolytes, especially potassium, are monitored. With prolonged courses, the function of the hypothalamic-pituitary-adrenal axis, bone density, eye health, infectious complications and signs of Cushing’s syndrome are assessed. The extent of monitoring depends on the dose, duration of treatment, age and coexisting diseases.

Urgent assessment is required in cases of difficulty breathing, swelling of the face or larynx, a sudden fall in blood pressure, impaired consciousness, pronounced muscle weakness, repeated vomiting, severe abdominal pain, black stools, vomiting blood, severe hyperglycaemia, seizures, psychosis, a sharp reduction in urine output or signs of a severe infection. After prolonged therapy, a combination of weakness, nausea, hypotension, hypoglycaemia and confusion may indicate adrenal insufficiency. Waiting in such a situation is dangerous because shock may develop.

When Boswellia is used, gastrointestinal tolerability and possible allergic reactions should be monitored. When using an ointment made from Nigella sativa and Scutellaria baicalensis, only the local reaction and changes in the lesion are monitored. Lack of improvement within several days, spread of the rash or the appearance of signs of infection requires discontinuation of the homemade formulation and clarification of the diagnosis.

Correct Discontinuation of Hydrocortisone

After a single administration or a very short course, systemic hydrocortisone can usually be discontinued without a prolonged dose reduction, although the specific decision depends on the dose, duration of treatment, repeated courses and previous use of other glucocorticoids. After prolonged systemic therapy, abrupt discontinuation is unacceptable: the dose is reduced gradually to allow the hypothalamic-pituitary-adrenal axis to restore its own cortisol secretion.

Reducing the dose too quickly may cause weakness, fatigue, nausea, reduced appetite, muscle and joint pain, headache, hypotension, hypoglycaemia, fever and recurrence of the underlying disease. A severe consequence is an adrenal crisis. A single discontinuation regimen cannot be used for every patient: it depends on the initial dose, duration of treatment, the disease and the results of adrenal function assessment.

In confirmed adrenal insufficiency treated with replacement therapy, hydrocortisone must not be discontinued independently. This is not temporary anti-inflammatory treatment but replacement of an essential hormone. During infection, high fever, injury or surgery, the dose may need to be increased temporarily, while vomiting may require a switch to parenteral administration. Sudden interruption of replacement therapy poses a direct threat to life.

Topical hydrocortisone used for a short course on a small area can usually be stopped immediately. After prolonged application, especially on the face and during frequent repeated courses, rebound dermatitis may develop with redness, burning and a rapid return of symptoms. In such situations, the frequency of application is sometimes reduced gradually while the skin barrier is restored and the cause of inflammation is clarified. A sudden return of the rash does not automatically mean that the skin “lacks hormones”: more often, it indicates persistent disease, disruption of the skin barrier or dependence on continuous suppression of inflammation.

A Reasonable Approach to Treatment

Hydrocortisone is justified when rapid and predictable anti-inflammatory action, emergency treatment or replacement of cortisol deficiency is required. In adrenal crisis, adrenal insufficiency, a severe allergic reaction and unstable systemic inflammation, substitution with an herbal remedy is unacceptable.

In chronic stable joint inflammation without a risk of organ failure, standardised Boswellia serrata extract may reduce the need for repeated systemic anti-inflammatory courses. In mild, limited, non-infected dermatitis, a topical formulation containing Nigella sativa and Scutellaria baicalensis may be used as a gentler option or as part of supportive care after the diagnosis has been established.

The aim of an integrative approach is not to mechanically replace a strong medicine with a weak one, but to distinguish between clinical situations. Where hydrocortisone is required, it should be used at the minimum effective dose and for the shortest necessary period. Where immediate hormonal immunosuppression is not needed, it is reasonable to choose options associated with a lower risk of skin atrophy, systemic metabolic complications and adrenal suppression.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or book an appointment via this link: https://asiabiopharm.com/konsultaciii/